In a year marked by economic uncertainty, regulatory shifts, and evolving therapeutic priorities, dealmaking in the pharmaceutical industry remains a critical lever for growth. IQVIA Pharma Deals Half-Year Review of 2025 offers a data-driven lens into where capital is flowing in global pharma, which assets are commanding premium valuations, and how top players are reshaping their pipelines.

Whether you're evaluating licensing opportunities, scouting M&A targets, or refining your portfolio, this report equips you with the insights to stay competitive and future-ready.

Read the review to uncover:

• The top M&A and licensing deals that defined H1 2025
• Deal activity by therapeutic area and development phase
• Value trends across M&A, licensing, and R&D collaborations
• Rankings of the most active pharmaceutical companies
• Strategic outlook for dealmaking in H2 2025

Highlights:

• M&A volume rose 11% year-over-year, but deal values declined as buyers favored bolt-on acquisitions over mega-deals.
• Licensing spend surged 37%, driven by strong demand for late-stage and de-risked assets.
• Collaborative R&D alliances fell 15%, continuing a post-pandemic decline despite rising interest in AI-driven platforms.
• Oncology remained the leading therapeutic area, while CNS investments gained momentum amid reduced oncology deal volume.

Download the report to benchmark your strategy, uncover high-value opportunities, and make smarter investment decisions for the second half of 2025.